These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 6629813

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C, Martínez A, Galalae R, Demanes J, Harsolia A, Schour L, Nuernberg N, Gonzalez J.
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml.
    Bastide C, Kuefer R, Loeffler M, de Petriconi R, Gschwend J, Hautmann R.
    Prostate Cancer Prostatic Dis; 2006; 9(3):239-44. PubMed ID: 16832384
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Estrogen and survival data in carcinoma of the prostate.
    Bennett AH, Dowd JB, Harrison JH.
    Surg Gynecol Obstet; 1970 Mar; 130(3):505-8. PubMed ID: 4905115
    [No Abstract] [Full Text] [Related]

  • 7. [Rate of survival in prostatic cancer with bone metastasis].
    Kuntz D, Ryckewaert A.
    Rev Fr Etud Clin Biol; 1969 Mar; 14(6):609-13. PubMed ID: 5824263
    [No Abstract] [Full Text] [Related]

  • 8. Endocrine treatment of prostate cancer: standard treatment and new perspectives.
    Boccardo F, Pace M.
    In Vivo; 1993 Mar; 7(5):423-4. PubMed ID: 8110985
    [Abstract] [Full Text] [Related]

  • 9. High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
    Morris MJ, Smaletz O, Solit D, Kelly WK, Slovin S, Flombaum C, Curley T, Delacruz A, Schwartz L, Fleisher M, Zhu A, Diani M, Fallon M, Scher HI.
    Cancer; 2004 May 01; 100(9):1868-75. PubMed ID: 15112267
    [Abstract] [Full Text] [Related]

  • 10. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T, Nutahara K, Higashihara E.
    J Urol; 2008 Oct 01; 180(4):1342-7. PubMed ID: 18707699
    [Abstract] [Full Text] [Related]

  • 11. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
    Okegawa T, Kinjo M, Nutahara K, Higashihara E.
    Int J Urol; 2006 Sep 01; 13(9):1197-201. PubMed ID: 16984552
    [Abstract] [Full Text] [Related]

  • 12. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases.
    Petrioli R, Rossi S, Caniggia M, Pozzessere D, Messinese S, Sabatino M, Marsili S, Correale P, Salvestrini F, Manganelli A, Francini G.
    Urology; 2004 Feb 01; 63(2):321-6. PubMed ID: 14972482
    [Abstract] [Full Text] [Related]

  • 13. Optimal hormonal therapy for advanced prostatic carcinoma.
    Goktas S, Crawford ED.
    Semin Oncol; 1999 Apr 01; 26(2):162-73. PubMed ID: 10597727
    [Abstract] [Full Text] [Related]

  • 14. [Study of the hormone-refractory prostate cancer clinical practice in an anti-cancer center].
    Zufferey L, Roques B, Fléchon A, Droz JP.
    Bull Cancer; 2001 Dec 01; 88(12):1213-21. PubMed ID: 11792613
    [Abstract] [Full Text] [Related]

  • 15. [Experiences with estramustinphosphate (Estracyt) in estrogen-resistant metastasizing prostatic cancer].
    Köller A, Lunglmayr G.
    Wien Med Wochenschr; 1983 Dec 01; 133(7):179-81. PubMed ID: 6868629
    [No Abstract] [Full Text] [Related]

  • 16. [Treatment of advanced metastasizing prostatic carcinoma].
    Lohse R, Schubert J.
    Dtsch Gesundheitsw; 1972 Jun 29; 27(26):1238-41. PubMed ID: 5076732
    [No Abstract] [Full Text] [Related]

  • 17. New agents in the therapy of hormone-refractory patients with prostate cancer.
    Kantoff PW.
    Semin Oncol; 1995 Feb 29; 22(1 Suppl 1):32-4. PubMed ID: 7532323
    [No Abstract] [Full Text] [Related]

  • 18. Long-term follow-up of radiotherapy for prostate cancer.
    Swanson GP, Riggs MW, Earle JD.
    Int J Radiat Oncol Biol Phys; 2004 Jun 01; 59(2):406-11. PubMed ID: 15145156
    [Abstract] [Full Text] [Related]

  • 19. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
    Arrizabalaga Moreno M, García González JI, Mora Durvan M, Díez Rodríguez JM, Esteban Artiaga R, Navarro Sebastián J, Castro Pita M, Paniagua Andrés P.
    Actas Urol Esp; 1997 Sep 01; 21(8):724-36. PubMed ID: 9412221
    [Abstract] [Full Text] [Related]

  • 20. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, Tsintavis A.
    Clin Cancer Res; 2004 Jul 01; 10(13):4398-405. PubMed ID: 15240528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.